Midcareer Investigator Award

职业生涯中期研究员奖

• 批准号: 8868051
• 负责人: MATTHEW RAYMOND SMITH
• 金额: $ 18.6万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-05 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8868051
• 关键词: Acetates; Adverse effects; Anabolism; Androgen Receptor; Androgens; Area; Award; Biological Markers; Body Composition; Bone Density; Cancer Center; Cancer Survivorship; Cessation of life; Clinical; Clinical Investigator; Clinical Research; Development; Dose; Funding; General Hospitals; Goals; Heterogeneity; Lead; Malignant Neoplasms; Malignant neoplasm of prostate; Massachusetts; Medical Oncologist; Mentors; Metabolic; Metabolism; Metastatic Neoplasm to the Bone; Metastatic Prostate Cancer; Methodology; Microfluidics; Molecular; Neoplasm Circulating Cells; New Agents; Peer Review; Peer Review Grants; Pharmaceutical Preparations; Prevention; Productivity; Receptor Signaling; Research; Research Activity; Research Personnel; Signal Pathway; Time; Training; Vascular Endothelial Growth Factor Receptor; abiraterone; castration resistant prostate cancer; catalyst; clinical care; deprivation; design; drug mechanism; effective therapy; improved; inhibitor/antagonist; male health; men; next generation; novel; patient oriented research; prevent; programs; resistance mechanism; response; small molecule; survivorship; therapy development

DESCRIPTION (provided by applicant): The broad long-term objectives of this K24 renewal are to enhance the research productivity of the candidate and to increase the pool of well-trained clinical researchers who can conduct patient-oriented research, compete for peer reviewed grants, and mentor the next generation of clinical investigators. The Specific Aims are to: (1) develop and expand the candidate's capabilities in patient-oriented research, and (2) mentor new investigators in patient-oriented research. The candidate is a medical oncologist with particular expertise in prostate cancer. He has a strong record of patient-oriented research, independent peer-reviewed funding, and effective mentoring. The candidate's clinical research program focuses on prostate cancer survivorship and the prevention and treatment of bone metastases. In the first 5 years of this K24, the candidate has helped improve the clinical care for men with prostate cancer by identifying previously unrecognized harms of androgen deprivation therapy and by developing effective new treatments for prostate cancer. In the first five years of this K24, the candidate has also successfully mentored 10 junior investigators in patient-oriented research. This K24 renewal coincides with important new directions in the candidate's research program. The research program has been developed and expanded around three research themes: survivorship, biomarkers, and novel therapy. This K24 renewal also coincides with the identification of three new mentees and planned expansion of mentoring responsibilities at Massachusetts General Hospital, Dana Farber Harvard Cancer Center, and the Harvard Catalyst. The support of this K24 renewal is essential to provide the candidate with the protected time necessary to develop and expand patient-oriented research and mentoring.

描述（由申请人提供）：此次K24更新的长期目标是提高候选人的研究效率，增加训练有素的临床研究人员的数量，他们可以进行以患者为导向的研究，竞争同行评审的资助，并指导下一代临床研究人员。具体目标是：(1)发展和扩大候选人在面向患者的研究方面的能力；(2)指导新的研究人员进行面向患者的研究。